These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17338591)

  • 1. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer's disease.
    Iliffe S
    CNS Drugs; 2007; 21(3):177-84. PubMed ID: 17338591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?
    Getsios D; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2007; 25(12):997-1006. PubMed ID: 18047386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.
    McNamee P; Vanoli A; Hutchings D; McKeith I; Bond J
    J Nutr Health Aging; 2010 Oct; 14(8):664-8. PubMed ID: 20922343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Counting costs. Patients will suffer from limits on Alzheimer's drugs.
    Page S
    Nurs Stand; 2005 May 25-31; 19(37):24-5. PubMed ID: 15938410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
    Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Not so NICE. A proposal from the National Institute for Clinical Excellence to withdraw treatments for Alzheimer's disease from the NHS has left support groups reeling.
    Heath H
    Nurs Older People; 2005 Apr; 17(2):8. PubMed ID: 15835500
    [No Abstract]   [Full Text] [Related]  

  • 8. Valued lives: Britain stirs outcry by weighing benefits of drugs versus price; government arm finds pills for Alzheimer's too costly, angering patients, Pfizer.
    Whalen J
    Wall St J (East Ed); 2005 Nov; ():A1, A11. PubMed ID: 16502534
    [No Abstract]   [Full Text] [Related]  

  • 9. Evidence and values: paying for end-of-life drugs in the British NHS.
    Chalkidou K
    Health Econ Policy Law; 2012 Oct; 7(4):393-409. PubMed ID: 23079299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological therapy for people with Alzheimer's disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs.
    Ballard C; Sorensen S; Sharp S
    J Alzheimers Dis; 2007 Aug; 12(1):53-9. PubMed ID: 17851194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.
    Jones RW; McCrone P; Guilhaume C
    Drugs Aging; 2004; 21(9):607-20. PubMed ID: 15260515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis.
    Neumann PJ
    Pharmacoeconomics; 2005; 23(6):537-41. PubMed ID: 15960551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
    Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
    Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
    Pfeil AM; Kressig RW; Szucs TD
    Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality, innovation, and value for money: NICE and the British National Health Service.
    Pearson SD; Rawlins MD
    JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north-west of England.
    Purandare N; Swarbrick C; Fischer A; Burns A
    Int J Geriatr Psychiatry; 2006 Oct; 21(10):961-4. PubMed ID: 16927408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Institute of Health and Clinical Excellence decision processes supported by UK High Court: the debate about the value of Alzheimer's disease drugs continues.
    Whitehouse PJ
    J Alzheimers Dis; 2008 Apr; 13(3):239-40. PubMed ID: 18567175
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.